# Immune Checkpoint Inhibitors: Response Rates in Solid Tumors

| Indication | Anti-PD-1 Overall Response Rate (ORR) | Anti-PD-1 + Anti-CTLA-4 ORR | Trial |
|---|---|---|---|
| **Melanoma** | 40% | 50% | CHECKMATE-067[1] |
| **MSI-H CRC*** | 28% | 46% | CHECKMATE-142[1] |
| **SCLC**** | 11% | 23% | CHECKMATE-032[2] |
| **RCC***** | 21.5% (2L) | 41.6% (1L) | CHECKMATE-025 (2L)[1]<br>CHECKMATE-214 (1L)[1] |

* Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
** Small Cell Lung Cancer
*** Renal Cell Carcinoma

References:


1. OPDIVO [package insert] Princeton, NJ: Bristol-Myers Squibb Company. Accessed July 11, 2018.
2. Checkmate-032 (Hellmann, J Thorac Oncol , Vol. 12 , Issue 1 , S393 - S394)


agenus